Loading
Journal of Cancer Biology
ISSN: 2692-7896
Volume 4, Issue 2, p38-53
Articles published in this issue are Open Access and licensed under Creative Commons Attribution License (CC BY NC) where the readers can reuse, download, distribute the article in whole or part by mentioning proper credits to the authors.
Tumor evolution: The road map to future cancer therapeutics
The common denominator among all is ignoring the most fundamental pillar on which the forward move of tumor mass is based, namely tumor evolution along the thermodynamics arrow of time. Tumor evolution in certain ways is akin to evolution of life on this planet, which has acquired higher levels of sophistication and diversity. Neoplastic transformation and its evolutionary path could be divided into three main phases: initiation, promotion, and progression. Our future cancer therapeutics is expected to intercept with this evolutionary path. This necessitates a deep understanding of the dynamics of this path, and the necessary means including AI, and Nano–delivery to execute this task.
J Cancer Biol, 2023, Volume 4, Issue 2, p38-39 | DOI: 10.46439/cancerbiology.4.052
Tumor microenvironment: The crossroad of normal state and cancer
The identification of comprising cells and composition of microenvironment, which is the result of many years of work in many research labs across the globe, has made it possible to see just the tip of iceberg. The dynamic and fluid nature of microenvironment, with its tumor agonistic and antagonistic cells at one end, and its intricate communication with tumor mass, is leaving us with many unanswered questions, both conceptually and functionally. Tumor associated macrophages, tumor associated fibroblasts, B and T regulatory cells, angiogenesis factors and many other cellular, and humeral factors, comprise elements of tumor microenvironment eco-system. Tissue resident macrophages, originating from bone marrow are among the tumor antagonists. However, the most puzzling of all are tissue resident macrophages that originate from the yolk sac of embryo and dispersed in all organs.
J Cancer Biol, 2023, Volume 4, Issue 2, p40-41 | DOI: 10.46439/cancerbiology.4.054
Investigation of CBL-b, c-CBL expressions in colorectal cancer patients and their relationship with clinicopathological characteristics
Colorectal cancer (CRC) is the most common gastrointestinal cancer and a major cause of cancer-related mortality worldwide. Molecular indicators of pathogenic factors that regulate CRC, which are known as oncogenes, are desirable for response to treatment and improvement of CRC patient management. Several risk factors play a role in the development of this disease, which can occur genetically, familial, or sporadically. CRC tumorigenesis is stimulated by the proto-oncogene β-catenin (wnt/β-catenin). Casitas B-lineage lymphoma (c-Cbl) inhibits CRC tumor growth through an unknown mechanism that affects nuclear β-catenin. The current objective of this study is to evaluate the expression levels of Cbl-b and c-Cbl genes to determine if their transcripts can be used as suitable diagnostic indicators. Additionally, we aim to investigate the correlation between clinicopathological information of CRC patients and the levels of Cbl-b and c-Cbl.
J Cancer Biol, 2023, Volume 4, Issue 2, p42-48 | DOI: 10.46439/cancerbiology.4.054
Turn up the MIC(A/B): Amplifying stress-ligand recognition to target iPSC derived immune cell therapies against tumors and diseased cell states
Cancer is a multifaceted disease that is overwhelming in the breadth and scope of its genetic diversity, tissue pathology, and response to therapy. In recent years, the development of novel chimeric antigen receptor (CAR) containing cell-based therapies has provided significant clinical benefit to patients with certain hematological malignancies. The overall response rates (ORR) of Food and Drug Administration (FDA) approved autologous CD19 CAR T cell products for the treatment of refractory and relapsed B cell lymphomas have reached approximately 80% in defined patient populations, with durable remissions of greater than several years. Regrettably, the deployment of these novel cell-based therapies against solid tumor indications has garnered much less enthusiasm due to disappointing clinical success. The intrinsic adaptability of solid tumors makes them particularly elusive for effective targeted treatment, in part due to their extensive cellular heterogeneity and antigen diversity, their capacity to evade immune responses through antigen escape, and their ability to establish immune suppressive microenvironments. Identifying and selecting appropriate tumor specific antigens that distinguish tumor cells from healthy tissue remains arguably one of the most essential requirements to develop efficacious solid tumor targeting cell-based therapies.
J Cancer Biol, 2023, Volume 4, Issue 2, p49-53 | DOI: 10.46439/cancerbiology.4.055
Fight tumor heterogeneity
Intratumor heterogeneity has attracted more and more attention in recent years. Heterogeneity is the driving force of tumor clone evolution. Chromosomal instability, somatic mutation, epigenetic modification and extrachromosomal DNA (ecDNA) contribute to tumor heterogeneity. The degree of such heterogeneity is extremely high.
Modulating the immunotolerant tumor microenvironment to enhance irreversible electroporation ablation therapy
Over the years, several ablation techniques, such as radiofrequency ablation (RFA), microwave ablation, and cryoablation, have been developed and implemented in the treatment of different cancers. Of these ablation technologies, RFA is the most widely used. RFA is a form of thermal ablation that relies on radio waves to produce an electrical current at the tip of an inserted electrode, thus allowing for heat production at the site of the tumor.
Harnessing innovation for the future of breast cancer management
Background: Breast cancer remains a major global health burden despite therapeutic advances, necessitating further innovations to address persistent challenges like therapeutic resistance, adverse effects, and mortality in subgroups. Emerging technologies offer promising opportunities in this regard through data-driven, precise, and personalized approaches.
A scoping review of outcome measures in ovarian cancer clinical trials
The incorporation of patient-reported outcomes (PROs) is essential for assessing whether a cancer treatment enhances overall patient well-being, beyond merely extending survival. This scoping review aimed to identify and analyze the use of PROs in ovarian cancer clinical trials.
Significance of BRCA genetic testing for preoperative breast cancer patients
Examining BRCA mutations in preoperative breast cancer patients is very important when selecting a surgical procedure. Although there are advantages and disadvantages associated with knowing about the presence of genetic mutations, including for the patient’s family, there are many benefits for the patient. BRCA genetic testing should be recommended for patients who are strongly suspected of being positive for a BRCA mutation.
Molecular signatures of aggressive pediatric liver cancer
Liver masses account for 5 to 6% of pediatric cancer, which includes hepatoblastoma (HBL) along with rare cases of hepatocellular carcinoma (HCC). The most dangerous form of pediatric liver cancer is aggressive HBL, which can be characterized by chemo-resistance and multiple nodules or metastases at diagnosis, all correlating with worse clinical prognosis. Despite intensive studies and a significant improvement in overall outcomes, very little is known about the key molecular pathways which determine the aggressiveness of pediatric liver cancer.
Deregulation of Slug/Snail2 and TGF-β crosstalk in airway epithelial stem/progenitor cells: A key link between COPD and lung cancer?
This commentary focuses on two recent publications showing deregulation of the transcription factor Slug/Snail2 and TGF-β function in primary bronchial basal/progenitor cells of patients with Chronic Obstructive Pulmonary Disease (COPD) and the impact on proliferation and the expression of genes involved in stem cell maintenance. We discuss the molecular mechanisms related to the exhaustion of airway basal stem/progenitor cells in tobacco smoke-induced COPD, as well as putative links between COPD and lung cancer at the molecular level.
Considering Taguchi method as a feature selection method in agent-based models of cancer disease: A mini-review
Cancer biology involves complex dynamics and interactions between cells and the tissue environment. Mathematical modeling and computer simulation can provide a powerful instrument for considering this complexity. Agent-based modeling is a particular discrete hybrid modeling method.
The tumor dose sensitivity matrix and stem cells in head and neck cancer
Radiation therapy (RT) is one of the pillars of locally advanced head and neck cancer (HNSCC) treatment in combination with cisplatin or epidermal growth factor receptor inhibitors. Despite a very high local tumor control rate, approximately 50% of patients with locally advanced disease will develop a recurrence.
Genetic mutations in the molecular pathogenesis of gastrointestinal stromal tumor
Gastrointestinal stromal tumors are mesenchymal tumors which predominantly originate from the interstitial cells of Cajal in the intestinal lining. Around ~85% of malignant GISTs possess activating mutations in the tyrosine kinase receptors KIT or PDGFRA. The driver mutations in genes other than KIT or PDGFRA account for around 15% GISTs and belong to highly heterogeneous groups called wild-type GISTs. Around 20–40% of WT-GISTS are deficient for the succinate dehydrogenase complex (SDHA, SDHB, SDHC, SDHD).
Epigenetics of pediatric liver cancer and potential therapy
The pediatric liver cancer hepatoblastoma (HBL) has a complex etiology which is not yet determined. In contrast to adult liver cancer hepatocellular carcinoma (HCC), pediatric HBL has a low rate of genetic mutations suggesting that other mechanisms play a critical role in development of this disease.
BRCA1 and BRCA2 mutation variants in early breast cancer confer added prognostic information
Metastatic breast cancer to brain carries poor prognostic features with increased risks of occurrence in Tripple- negative and HER- positive breast tumors. In addition, tumors with mutated BRCA tumors, carry as well increased metastatic incidence. However, new clinical evidence suggest distinct clinical features between BRCA1 or BRCA2 mutated breast cancer and brain metastasis.
The role of MRI in detecting and characterizing brain metastases from breast cancer
Brain metastases are a feared complication of breast cancer, occurring in 15-25% of patients and being associated with poor prognosis and reduced quality of life. Magnetic resonance imaging (MRI) is an advanced technique that uses powerful magnetic fields and radio waves to produce detailed three-dimensional (3D) images of the brain's neuroanatomy and any potential pathology, especially in the management of brain metastases.
Identification and validation of N7-methylguanosine-associated gene NCBP1 as prognostic and Prognostic immune-associated biomarkers in breast cancer patients
Epigenetics is the study of heritable modifications to gene expression, such as DNA methylation, histone modifications, and RNA modifications, that do not alter the nucleotide sequence of the corresponding gene. Recently, RNA modification has emerged as a novel research focus.
Cancer-related anxiety, COVID-19, and the oncologist: the formation of a ‘Balint’ process group
The management of anxiety and distress in patients with cancer is stressful for the oncology clinicians who treat them. Unfortunately, psychosocial care for patients with cancer is not universally available or standardized. Referrals from oncology services to psychological serves are often not initiated early enough, may not be encouraged from medicine or surgical services, and are subsequently foregone or patients do not follow up beyond a single appointment.
Approach to testicular adrenal rest tumors in children and adolescents with congenital adrenal hyperplasia
Congenital adrenal hyperplasia (CAH) is a disorder affecting cortisol biosynthesis in the adrenal cortex [1]. 21-hydroxylase deficiency is the most frequent reason for CAH, with an incidence between 1:10.000 and 1:20.000 [2]. Due to the lack of enzyme function, patients with any enzyme deficiency cannot synthesize cortisol effectively.
CD133 and centrosomes: How CD133 inhibits autophagy and induces the undifferentiated state of cancer cells at centrosomes
CD133 is a transmembrane protein that mainly localizes to the plasma membrane of normal stem cells as well as cancer stem cells, and is widely known as a cancer stem cell marker. CD133 was recently shown to localize in the cytoplasm; however, its transport pathway and functions currently remain unknown.
The Oncogenic Role of ADAR1-Mediated RNA Editing in Thyroid Cancer
A-to-I RNA modifications performed by the adenosine deaminase acting on RNA (ADAR) protein family are gaining traction as important mechanisms in cancer biology. A-to-I RNA editing changes adenosine to inosine on double stranded RNA, which co-transcriptionally alters transcript sequence and structure. A number of microRNA (miRNA) precursors are known to be edited by the ADARs, which alters the expression and/or function of the mature miRNA.
Machine learning for precision medicine in cancer: Transforming drug discovery and treatment
Machine learning (ML) is a branch of artificial intelligence that uses an algorithm to process the data, retrieve valuable information, learn from it, find a pattern, and make predictions. Manual data analyses suffer from several disadvantages including it is time-consuming and subject to error.
A vicious cycle happened in the progress of hyperhomocysteinemia, the same may exist in the development of cancer
Homocysteine (Hcy) metabolism is at the intersection of two metabolic pathways: remethylation and trans-sulfuration, which abnormality can result in hyperhomocysteinemia (HHcy). In the past few years our team has been working on the molecular mechanism of HHcy development.